Pimavanserin clinical trials
Also written Nuplazid and ACP-103.
How each study uses pimavanserin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pimavanserin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Apr 2016 · NUPLAZID · NDA 207318 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2004 | 3 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 4 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 16
ACADIA Pharmaceuticals Inc. (25) · Baylor College of Medicine (2) · VA Office of Research and Development (2) · Tasly Pharmaceutical Group Co., Ltd (1) · University Hospital, Strasbourg, France (1) · Humanis Saglık Anonim Sirketi (1) · Joseph Jankovic (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antipsychotics source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test pimavanserin.
- Jan 2027Pimavanserin and Aggression and Social Cognition.Phase 2 · Ohio State University
- Jun 2027Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesPhase 4 · Vanderbilt University Medical Center
- Jul 2027Pimavanserin for Insomnia in Veterans With PTSDPhase 2 · VA Office of Research and Development
- Oct 2027Pimavanserin vs. Quetiapine for Treatment of Parkinson's PsychosisPhase 4 · VA Office of Research and Development
- Oct 2027Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum DisorderPhase 2 · New York State Psychiatric Institute
Studies
Open first, then newest update. How each study uses pimavanserin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 43
- Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT06592833Written as PimavanserinHow we know
- Psilocybin Efficacy With or Without Pimavanserin PretreatmentRecruitingPhase 1/2Johns Hopkins UniversityNCT07610135Written as PimavanserinHow we know
- Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum DisorderRecruitingPhase 2New York State Psychiatric InstituteNCT05999240Written as Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]How we know
- Pimavanserin vs. Quetiapine for Treatment of Parkinson's PsychosisRecruitingPhase 4VA Office of Research and DevelopmentNCT04373317Written as PimavanserinHow we know
- Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesRecruitingPhase 4Vanderbilt University Medical CenterNCT05357612Written as PimavanserinHow we know
- Pimavanserin for Insomnia in Veterans With PTSDRecruitingPhase 2VA Office of Research and DevelopmentNCT05441280Written as pimavanserinHow we know
- Investigating the Neuropsychological Effects of 5-HT2a AntagonismRecruitingNot applicableUniversity of OxfordNCT07022366Written as Pimavanserin 10mgHow we know
- Comparing Antipsychotic Medications in LBD Over TimeRecruitingPhase 4The University of Texas Health Science Center at San AntonioNCT05590637Written as PimavanserinHow we know
- Pimavanserin and Aggression and Social Cognition.RecruitingPhase 2Ohio State UniversityNCT05895513Written as Pimavanserin 34 mgHow we know
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedPhase 3Tasly Pharmaceutical Group Co., LtdNCT06068465Written as pimavanserin tartrateHow we know
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.CompletedPhase 2University Hospital, Strasbourg, FranceNCT03947216Written as Active drug: pimavanserin 17mg (2 strength tablets)How we know
- Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderTerminatedPhase 2/3ACADIA Pharmaceuticals Inc.NCT05555615Written as PimavanserinHow we know
- Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderCompletedPhase 2/3ACADIA Pharmaceuticals Inc.NCT05523895Written as PimavanserinHow we know
- Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaTerminatedPhase 3ACADIA Pharmaceuticals Inc.NCT03121586Written as PimavanserinHow we know
- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT04531982Written as PimavanserinHow we know
- Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisCompletedPhase 4ACADIA Pharmaceuticals Inc.NCT04292223Written as PimavanserinHow we know
- A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT03575052Written as PimavanserinHow we know
- Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT03623321Written as PimavanserinHow we know
- Pimavanserin for Sleep in Parkinson DiseaseWithdrawnEarly Phase 1State University of New York - Downstate Medical CenterNCT05796167Written as PimavanserinHow we know
- The Sub-Sero StudyWithdrawnPhase 2Bjorn H. EbdrupNCT03994965Written as Pimavanserin 34 milligrams (MG) [Nuplazid]How we know
See all 43 studies that test pimavanserin →
Given beside what is tested · 2 — pimavanserin is usual care or a partner of the new treatment
Codes
What other systems call pimavanserin · ClinicalTrials.gg INT004917
- MeSH (NLM) C510793pimavanserinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) JZ963P0DIKPIMAVANSERINConfirmed FDA, NLM, Wikidata
- RxNorm 1791685Confirmed FDA, Wikidata
- Wikidata Q7194603pimavanserinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76444PimavanserinOne source FDA
- DrugBank DB05316One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C510793 | pimavanserin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | JZ963P0DIK | PIMAVANSERIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1791685 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7194603 | pimavanserin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76444 | Pimavanserin | One source FDA |
| DrugBank | DB05316 | — | One source Wikidata |
Also registered as pimavanserin tartrate (UNII NA83F1SJSR · RxNorm 1791686).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.